Long-chain EPA/DHA omega-3 fatty acid supplementation can be co-preventative and co-therapeutic. Current research suggests increasing accumulated long chain omega-3s for health benefits and as natural medicine in several major diseases. But many believe plant omega-3 sources are nutritionally and therapeutically equivalent to the EPA/DHA omega-3 in fish oil. Although healthy, precursor ALA bio-conversion to EPA is inefficient and production of DHA is nearly absent, limiting the protective value of ALA supplementation from flax-oil, for example. Along with pollutants certain fish acquire high levels of EPA/DHA as predatory species. However, the origin of EPA/DHA in aquatic ecosystems is algae. Certain microalgae produce high levels of EPA or DHA. Now, organically produced DHA-rich microalgae oil is available. Clinical trials with DHA-rich oil indicate comparable efficacies to fish oil for protection from cardiovascular risk factors by lowering plasma triglycerides and oxidative stress. This review discusses 1) omega-3 fatty acids in nutrition and medicine; 2) omega-3s in physiology and gene regulation; 3) possible protective mechanisms of EPA/DHA in major diseases such as coronary heart disease, atherosclerosis, cancer and type 2 diabetes; 4) EPA and DHA requirements considering fish oil safety; and 5) microalgae EPA and DHA-rich oils and recent clinical results.
Keywords: Omega-3s, Schizochytrium, Fish oil, EPA, DHA
It’s Time for An Epigenomics Roadmap of Heart Failure
Current Genomics Cardiac Metabolism in Myocardial Ischemia
Current Pharmaceutical Design Functional Foods: Salient Features and Clinical Applications
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Cardioprotection by Conditioning Mimetic Drugs
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Tocotrienols and Cardiovascular Health
Current Pharmaceutical Design From Physiome to Pathome: A Systems Biology Model of Major Depressive Disorder and the Psycho-Immune-Neuroendocrine Network
Current Psychiatry Reviews Treating High Density Lipoprotein Cholesterol (HDL-C): Quantity Versus Quality
Current Pharmaceutical Design Current Drug Targets for Antihyperlipidemic Therapy
Mini-Reviews in Medicinal Chemistry Heart Failure Models: Traditional and Novel Therapy
Current Vascular Pharmacology Percutaneous Treatment of Aortic Valve Disease: Contemporary Overview and Future Trends
Current Pharmaceutical Design Value of Abnormal Fetal Cardiac Axis in the Fetal Congenital Heart Disease
Current Medical Imaging Carvedilol: Just Another Beta-Blocker or a Powerful Cardioprotector?
Cardiovascular & Hematological Disorders-Drug Targets Blood Atherogenicity as a Target for Anti-atherosclerotic Therapy
Current Pharmaceutical Design Nitrogen and Sulfur Co-doped Fluorescent Carbon Dots for the Detection of Morin and Cell Imaging
Current Analytical Chemistry Heart Failure in South America
Current Cardiology Reviews Fibrosis, Enzymatic and Non-Enzymatic Cross-Links in Hypertensive Heart Disease
Cardiovascular & Hematological Disorders-Drug Targets The Stress Response: Implications for the Clinical Development of Hsp90 Inhibitors
Current Cancer Drug Targets Does HbA1cc Play a Role in the Development of Cardiovascular Diseases?
Current Pharmaceutical Design Carotid Artery Atherosclerosis: What is the Evidence for Drug Action?
Current Pharmaceutical Design Effects of Pulmonary Blood Flow on Respiratory Mechanics: Measurements by the End-Inflation Occlusion Method in Healthy Rats After Acute Blood Volume Expansion
Current Respiratory Medicine Reviews